ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 2.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,291 shares of the specialty pharmaceutical company’s stock after selling 207 shares during the period. The Manufacturers Life Insurance Company’s holdings in ANI Pharmaceuticals were worth $554,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Innealta Capital LLC purchased a new position in shares of ANI Pharmaceuticals during the second quarter valued at approximately $65,000. Ridgewood Investments LLC purchased a new position in shares of ANI Pharmaceuticals during the 2nd quarter worth $85,000. XTX Topco Ltd acquired a new stake in shares of ANI Pharmaceuticals during the second quarter worth $207,000. Profund Advisors LLC purchased a new stake in shares of ANI Pharmaceuticals in the second quarter valued at $225,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in ANI Pharmaceuticals in the second quarter valued at $228,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have commented on the company. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday. Truist Financial upped their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Piper Sandler started coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They set an “overweight” rating and a $68.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $77.71.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $56.59 on Friday. The firm’s fifty day simple moving average is $58.01 and its 200 day simple moving average is $60.31. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a twelve month low of $51.79 and a twelve month high of $70.81. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -102.89 and a beta of 0.73.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. During the same quarter in the previous year, the firm posted $1.05 earnings per share. The firm’s quarterly revenue was up 12.5% on a year-over-year basis. As a group, equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Nikhil Lalwani sold 33,481 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the sale, the chief executive officer now directly owns 370,378 shares of the company’s stock, valued at approximately $21,478,220.22. The trade was a 8.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the transaction, the senior vice president now directly owns 49,059 shares of the company’s stock, valued at $2,943,540. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 34,731 shares of company stock worth $2,015,861 in the last 90 days. 12.70% of the stock is owned by company insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.